About AGI Therapeutics
AGI Therapeutics is a company based in Dublin (Ireland) founded in 2005 was acquired by Aravis in January 2012. AGI Therapeutics operates in a competitive market with competitors including aTyr Pharma, ReCode Therapeutics, GEn1E, Enterprise Therapeutics and Ikaria, among others.
- Headquarter Dublin, Ireland
- SectorsHealthcare
- Website agitherapeutics.com
- Social LinkedIn
- Acquired by Aravis (Jan 2012)
Investors in AGI Therapeutics
AGI Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Aravis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Growth capital is provided by Aravis for Swiss high-tech companies. | – | aravis.ch | Switzerland |
Investor details for AGI Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of AGI Therapeutics
2 dated milestones of AGI Therapeutics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded AGI Therapeutics is founded.
- Exit Acquired by Aravis.
Competitors of AGI Therapeutics
AGI Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, ReCode Therapeutics, GEn1E, Enterprise Therapeutics and Ikaria, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| atyrpharma.com | 2005 | San Diego, United States | $171.52M | 65 | Protein biologics are developed for treating rare diseases. | |
| recodetx.com | 2015 | Menlo Park, United States | $371M | – | Precision medicines for lung-related diseases are developed. | |
| gen1e.com | 2018 | Palo Alto, United States | $17.15M | – | Developer of therapeutics for the treatment of inflammatory and rare diseases | |
| enterprisetherapeutics.com | 2014 | Brighton, United Kingdom | $86.19M | 9 | Developer of therapeutic solutions for the treatment of respiratory diseases such as cystic fibrosis | |
| ikaria.com | 2005 | Hampton, United States | $434.92M | 429 | Therapies for respiratory-related cardiopulmonary disorders are developed. | |
| pulmatrix.com | 2003 | Lexington, United States | $67.11M | 28 | Developer of therapeutics for the treatment of respiratory diseases | |
| veronapharma.com | 2005 | London, United Kingdom | $56.02M | 27 | Respiratory disease drugs for asthma and COPD are developed. | |
| intermune.com | 1998 | Brisbane, United States | – | 359 | Therapies in pulmonology and orphan fibrotic diseases. |
Detailed competitors of AGI Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to AGI Therapeutics
10 companies that operate in the same segment as AGI Therapeutics (Pulmonology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Cancer detection diagnostics assays are developed and offered. | 2005 | Boulder, Colorado, United States | USD 200.16 M | USD 88.5 M | 273 | |
Therapeutic devices for nasal breathing improvement are developed. | 2011 | Sunnyvale, California, United States | USD 176.4 M | – | 66 | |
Non-invasive breath-based diagnostics for cancer and infectious diseases are developed. | 2004 | Cambridge, Cambridgeshire, United Kingdom | USD 166.55 M | – | 202 | |
Protein biologics are developed for treating rare diseases. | 2005 | San Diego, California, United States | USD 171.52 M | USD 190 K | 59 | |
Therapeutics for rare respiratory diseases are developed by Savara Pharma. | 2008 | Austin, Texas, United States | USD 67.82 M | – | 59 | |
Developer of smart devices for treating pulmonary diseases | 1998 | Redwood City, California, United States | USD 280.91 M | USD 90.5 M | 291 | |
A norovirus vaccine is developed for infection prevention. | 2021 | Boston, Massachusetts, United States | USD 135 M | – | 14 | |
Oral small molecule drugs for chronic diseases are developed. | 2017 | San Francisco, California, United States | USD 233 M | – | 163 | |
Precision medicines for lung-related diseases are developed. | 2015 | Menlo Park, California, United States | USD 371 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about AGI Therapeutics
AGI Therapeutics was founded in 2005.
AGI Therapeutics is headquartered in Dublin, Ireland.
AGI Therapeutics was founded in 2005 in Dublin, Ireland, as a specialty pharmaceutical company focused on treatments for lung-related conditions. Operations center on developing targeted drug delivery systems, with the lead candidate AGI-350 undergoing preclinical testing for direct lung administration. Data related to AGI-001, s-pindolol, is licensed from external sources. The company went public in 2006 and was later acquired by Aravis, a member of Vidara Therapeutics.
AGI Therapeutics's top competitors include aTyr Pharma, ReCode Therapeutics and Pulmatrix.
AGI Therapeutics has 1 investor. Key investors include Aravis.
Yes. AGI Therapeutics was acquired by Aravis in January 2012.